Medpace (NASDAQ:MEDP) Updates FY 2026 Earnings Guidance

Medpace (NASDAQ:MEDP) updated its FY 2026 earnings guidance on Monday. The company provided EPS guidance of 16.680-17.500 for the period, compared to the consensus EPS estimate of 15.830. The company issued revenue guidance of $2.8 billion-$2.9 billion, compared to the consensus revenue estimate of $2.7 billion.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Robert W. Baird set a $613.00 price target on shares of Medpace in a report on Friday, October 24th. Mizuho set a $660.00 target price on shares of Medpace in a report on Friday, January 9th. Wall Street Zen raised shares of Medpace from a “hold” rating to a “buy” rating in a report on Saturday, January 17th. TD Cowen restated a “sell” rating on shares of Medpace in a research report on Friday, October 24th. Finally, BMO Capital Markets initiated coverage on Medpace in a research report on Thursday, November 13th. They issued a “market perform” rating and a $600.00 price objective on the stock. Two analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Reduce” and an average target price of $491.27.

Medpace Stock Down 2.2%

NASDAQ:MEDP traded down $11.69 during midday trading on Monday, hitting $530.35. The company had a trading volume of 790,679 shares, compared to its average volume of 273,651. The company has a market capitalization of $14.94 billion, a PE ratio of 37.09, a P/E/G ratio of 1.82 and a beta of 1.42. Medpace has a 52-week low of $250.05 and a 52-week high of $628.92. The stock’s fifty day moving average price is $578.30 and its 200-day moving average price is $539.57.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings results on Monday, February 9th. The company reported $4.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.18 by $0.49. Medpace had a return on equity of 91.88% and a net margin of 18.36%.The firm had revenue of $708.45 million during the quarter, compared to analyst estimates of $689.53 million. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, research analysts forecast that Medpace will post 12.29 earnings per share for the current year.

Insiders Place Their Bets

In other news, VP Susan E. Burwig sold 20,000 shares of Medpace stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $609.15, for a total value of $12,183,000.00. Following the transaction, the vice president owned 27,500 shares in the company, valued at approximately $16,751,625. The trade was a 42.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Kevin M. Brady sold 3,000 shares of the business’s stock in a transaction dated Friday, November 21st. The shares were sold at an average price of $590.35, for a total value of $1,771,050.00. Following the completion of the sale, the chief financial officer directly owned 6,000 shares of the company’s stock, valued at approximately $3,542,100. This trade represents a 33.33% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 320,192 shares of company stock valued at $192,909,762 over the last quarter. 20.30% of the stock is owned by corporate insiders.

Institutional Trading of Medpace

Institutional investors have recently made changes to their positions in the stock. Sivia Capital Partners LLC bought a new stake in Medpace during the 2nd quarter valued at approximately $296,000. Harvest Fund Management Co. Ltd bought a new position in shares of Medpace in the 3rd quarter worth approximately $258,000. Sunbelt Securities Inc. lifted its stake in shares of Medpace by 12.3% in the 3rd quarter. Sunbelt Securities Inc. now owns 464 shares of the company’s stock valued at $239,000 after purchasing an additional 51 shares during the period. Florida Financial Advisors LLC purchased a new position in shares of Medpace in the 2nd quarter valued at approximately $233,000. Finally, PharVision Advisers LLC bought a new stake in shares of Medpace during the third quarter valued at approximately $230,000. Hedge funds and other institutional investors own 77.98% of the company’s stock.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.